Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00346814

Enrollment

Unknown

Registered

2006-06-30

Start date

2007-07-31

Completion date

2024-11-30

Last updated

2024-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy of Prematurity

Keywords

Retinopathy of prematurity, antiangiogenic therapy

Brief summary

Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP and inhibition of VEGF expression in the neovascular phase might prevent destructive neovascularization in ROP. The aim of this study is to determine the safety and efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity

Interventions

DRUGintravitreal injection

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

1 Months to 12 Months

Healthy volunteers

Inclusion criteria

* Retinopathy of prematurity stages III, IV and V in which we can not treat with laser o cryotherAPY

Exclusion criteria

* PATIENTS THAT COULD BE TREATED WITH CRYOTHERAPY OR LASER

Design outcomes

Primary

Measure	Time frame
Clinical appearance	—

Countries

Mexico

Contacts

Primary ContactHugo Quiroz-Mercado, MD

retinamex@yahoo.com525510841400

Backup ContactMaria A Martínez-Castellanos, MD